Get started
Schrodinger, Inc.SS

Schrodinger, Inc.

19.96USDR
−0.30−1.48%
At close at Mar 28, 22:50 GMT
USD
No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

SDGR trade ideas

SDGR - Bullish divergenceSDGR has been in an uptrend since breaking above its Base Formation neckline around $36.30, experienced several retracements of between 38.2% to 50% of each mini swings on the way up. Its most recent retracement is more "severe", now at 61.8% retracement. And with Earnings expected just round the corner (on 2nd Aug), it appears there is some "fear" leading to earnings announcement. Bullish divergence has begun to appear between price and RSI, hence it would be interesting to see if earnings would be the catalyst for the next rebound. NOT suggesting to take a position now (before earnings release) unless you are prepared for earnings risks. Disclaimer: Just my 2 cents and not a trade advice. Kindly do your own due diligence and trade according to your own risk tolerance and don't forget that money management is important! Take care and Good Luck!
N
by Juliac
9
SDGR - buy it now or wait for it to break higher?As a trade, it's probably safer to wait for SDGR to break through $78 and 79, but I took a half position this week. My conjecture is that the S1 pivot will provide stronger support, than the resistance to be faced at R1. More importantly, I believe the broader market trend (bullish, with momentum) will help advance SDGR. Looking for low to mid 80's target price but think it has more upside than that. Bought shares not options on SDGR. Note: YTD linear regression channel shows mean price of $67 currently. SDGR has been trying to move past +1 standard deviation bound since June 24th. Has been range bound since March 4 earnings release.
NLong
by goledger
Short Term OpportunityThey have negative EPS and not acceptable growth and income (~100M$) for a 4.5B $ company, soon the earnings will arrive and my guess is that price will drop because some investors will not like the numbers. But then the technical rational players will leave the arena and the irrational hype will start Results can be found "improving" for some :) and then price will go up because people will be amazed about how complicated software they use in discovering new molecules for drug development and sh.t . and the next bull run will start. I cannot predict future of course but I will bet on it :)
N
by Fantasmagorya
1
Cup and Handle Earnings 3-4. Large effective Volume on Friday. No rising wedges noted in yearly chart. Up quite a bit today so perhaps wait for a good entry. This gapped up at open and I am not sure why? Perhaps smart money trying to skip over resistance...not sure but it is now over the prior high. Not a recommendation.. Schrödinger, Inc. provides computational platform to accelerate drug discovery and materials design for biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. The company operates through two segments, Software and Drug Discovery. Its segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment develops a pipeline of preclinical and clinical drug discovery programs through its computational platform in collaboration with pharmaceutical companies. Schrödinger, Inc. has strategic collaborations with Twist Bioscience Corporation; Thermo Fisher Scientific to extend the use of cryo-EM in connection within silico compound screening to accelerate drug discovery; and Bristol Myers Squibb Company to discover, develop, and commercialize therapeutics in multiple disease areas. The company was founded in 1990 and is based in New York.
NLong
by lauralea
SDDGR: Selling Shovels During Gold RushWe are in the midst of a biotech boom. SDGR sits to profit greatly, selling cost/time saving software. They sell drug/material discovery software to biotechs and pharma companies. They also fully or jointly own some early stage/preclinical drug programs as well. Here are the investment highlights I believe are key. 1- Their physics based software makes new drug/material discovery cheaper/faster than traditional ways. This first step is the most costly/lengthy part in creating new drugs/materials. 2- They are a biotech in the respect that they are owners/co-owners of certain compounds in ongoing development/trails, giving them enormous upside. Joint ventures are as far as phase 2. 3- Strong balance sheet behind a secondary offering in August. Roughly 3.5 years worth of operating expenses in cash on the books. 4- Strong partnerships with big pharma such as Bristol-Meyers. Ongoing focus on research and development, putting 65% of revenue towards it. 5- Smart money is in on this. Bill/Melinda Gates foundation, billionaire investor David Shaw and his old life science hedge fund Deerfield along with another MP from Deerfield are all 10% owners. 6- Technically, it is also in a nice set up. It had been trading in a pretty tight channel before yesterdays' nonlogical sell off (no news). It has had a nice rebound today and I am expecting it to make a push back to that $97 resistance level. If it can break that, I think a move to the $130s is in store within the next 6 months
NLong
by RobertTheTrader
1